Last reviewed · How we verify
Adjuvant tislelizumab plus lenvatinib
Adjuvant tislelizumab plus lenvatinib is a PD-1 inhibitor + multi-targeted tyrosine kinase inhibitor combination Small molecule drug developed by Guangxi Medical University. It is currently in Phase 3 development for Adjuvant treatment of hepatocellular carcinoma (Phase 3).
Tislelizumab blocks PD-1 on immune cells to enhance anti-tumor immunity, while lenvatinib inhibits multiple receptor tyrosine kinases to suppress tumor angiogenesis and growth.
Tislelizumab blocks PD-1 on immune cells to enhance anti-tumor immunity, while lenvatinib inhibits multiple receptor tyrosine kinases to suppress tumor angiogenesis and growth. Used for Adjuvant treatment of hepatocellular carcinoma (Phase 3).
At a glance
| Generic name | Adjuvant tislelizumab plus lenvatinib |
|---|---|
| Sponsor | Guangxi Medical University |
| Drug class | PD-1 inhibitor + multi-targeted tyrosine kinase inhibitor combination |
| Target | PD-1 (tislelizumab); FGFR, VEGFR, RET, KIT (lenvatinib) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Tislelizumab is a humanized anti-PD-1 monoclonal antibody that restores T-cell-mediated immune responses against cancer cells. Lenvatinib is a multi-targeted tyrosine kinase inhibitor that blocks FGFR, VEGFR, RET, and KIT signaling, reducing tumor vascularity and proliferation. The combination leverages immunotherapy with targeted anti-angiogenic therapy to enhance overall anti-tumor efficacy.
Approved indications
- Adjuvant treatment of hepatocellular carcinoma (Phase 3)
Common side effects
- Fatigue
- Hypertension
- Diarrhea
- Decreased appetite
- Immune-related adverse events (e.g., hepatitis, pneumonitis)
- Proteinuria
Key clinical trials
- Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC (PHASE2)
- Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model (PHASE2)
- Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC (PHASE2)
- Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation (PHASE3)
- Tislelizumab Plus TKI as Adjuvant Therapy Versus Active Surveillance in Patients With HCC (PHASE2)
- Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma. (PHASE2)
- Tislelizumab Combined With Lenvatinib and GEMOX Versus Tislelizumab Combined With GEMOX in Conversion Therapy of ICC and GBC. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adjuvant tislelizumab plus lenvatinib CI brief — competitive landscape report
- Adjuvant tislelizumab plus lenvatinib updates RSS · CI watch RSS
- Guangxi Medical University portfolio CI
Frequently asked questions about Adjuvant tislelizumab plus lenvatinib
What is Adjuvant tislelizumab plus lenvatinib?
How does Adjuvant tislelizumab plus lenvatinib work?
What is Adjuvant tislelizumab plus lenvatinib used for?
Who makes Adjuvant tislelizumab plus lenvatinib?
What drug class is Adjuvant tislelizumab plus lenvatinib in?
What development phase is Adjuvant tislelizumab plus lenvatinib in?
What are the side effects of Adjuvant tislelizumab plus lenvatinib?
What does Adjuvant tislelizumab plus lenvatinib target?
Related
- Drug class: All PD-1 inhibitor + multi-targeted tyrosine kinase inhibitor combination drugs
- Target: All drugs targeting PD-1 (tislelizumab); FGFR, VEGFR, RET, KIT (lenvatinib)
- Manufacturer: Guangxi Medical University — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Adjuvant treatment of hepatocellular carcinoma (Phase 3)
- Compare: Adjuvant tislelizumab plus lenvatinib vs similar drugs
- Pricing: Adjuvant tislelizumab plus lenvatinib cost, discount & access